Innovating Works
nPL4GBM: Clinical validation of NANO-PL: a hydrogel-based formulation of a small molecule for a highly target... TARGTEX SA tramitó un HORIZON EUROPE: HORIZON-EIC-2023-ACCELERATOR-01 Glioblastoma (GBM) is considered the highest unmet need in oncology. The average life expectancy of GBM patients is 12-18 months, and the 5-...
2024-03-13 - 2026-02-28 | Financiado
Lottare GBM: LOcalized Targeted Therapy to Avoid REcurrent GlioBlastoma Multiforme TARGTEX SA tramitó un H2020: H2020-EIC-SMEInst-2018-2020 TargTex is a newly founded Portuguese startup with a novel concept to tackle the most lethal type of brain tumor – Glioblastoma Multiforme (...
2019-11-28 - 2020-05-31 | Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.